{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:25:13Z","timestamp":1793849113741,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clinthera.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:03:09Z","timestamp":1782878589000},"page":"e8-e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Stevens\u2013Johnson Syndrome\/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration"],"prefix":"10.1016","volume":"48","author":[{"given":"Huihui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.06.008_bib0001","article-title":"Analysis of the global burden of disease study highlights the global, regional, and national trends of idiopathic epilepsy epidemiology from 1990 to 2019","volume":"36","author":"Zhang","year":"2023","journal-title":"Prev Med Rep"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0002","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.2174\/0118715273275793231030060833","article-title":"Anti-seizure Medications: challenges and opportunities","volume":"23","author":"Tandon","year":"2024","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2494685","article-title":"Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysis","author":"Wu","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0004","article-title":"Severe cutaneous adverse reaction to lamotrigine: a case of Stevens\u2013Johnson Syndrome in a psychiatric patient","volume":"17","author":"Shingala","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/07853890701753664","article-title":"Stevens\u2013Johnson syndrome: pathogenesis, diagnosis, and management","volume":"40","author":"Hazin","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110722","article-title":"Psychiatric disorders associated with newer antiseizure medications: a real-world disproportionality analysis of FDA adverse event reporting system","volume":"172","author":"Li","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase\u00ae","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Safety"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/20420986251405091","article-title":"Evaluating seizures associated with novel antineoplastic agents during breast cancer treatment using the Food and Drug Administration Adverse Event Reporting System and Canada Vigilance Adverse Reaction Online Database","volume":"16","author":"Sha","year":"2025","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/ph15010027","article-title":"Analysis of factors associated with hiccups using the FAERS database","volume":"15","author":"Hosoya","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0010","first-page":"1295","article-title":"Etoricoxib and its hidden risks: a case-based review of dermatological, hematological, and cardiovascular complications","volume":"24","author":"Ansari","year":"2025","journal-title":"EXCLI J"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0011","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2023.02.072","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis","volume":"90","author":"Wei","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and Consensus on pharmacogenomic testing in psychiatry","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0013","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.alit.2025.05.002","article-title":"Updates in the pathogenesis of SJS\/TEN","volume":"74","author":"Justice","year":"2025","journal-title":"Allergol Int"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1432759","article-title":"Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example","volume":"15","author":"Xiong","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr Protoc Bioinformatics"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0017","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033985","article-title":"Genetic association between ankylosing spondylitis and major depressive disorders: shared pathways, protein networks and the key gene","volume":"102","author":"Dong","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0018","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0019","doi-asserted-by":"crossref","first-page":"D1432","DOI":"10.1093\/nar\/gkac1074","article-title":"TOXRIC: a comprehensive database of toxicological data and benchmarks","volume":"51","author":"Wu","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2023.167904","article-title":"Efficient analysis of toxicity and mechanisms of environmental pollutants with network toxicology and molecular docking strategy: acetyl tributyl citrate as an example","volume":"905","author":"Huang","year":"2023","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2024.117434","article-title":"Effect of Acetyl tributyl citrate on bone metabolism based on network toxicology and molecular docking technology","volume":"289","author":"Lin","year":"2025","journal-title":"Ecotoxicol Environ Saf"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1027112","article-title":"Exploring the mechanism of Alisma orientale for the treatment of pregnancy induced hypertension and potential hepato-nephrotoxicity by using network pharmacology, network toxicology, molecular docking and molecular dynamics simulation","volume":"13","author":"Liao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0023","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0024","article-title":"Exploring the mechanism of curcumin in the treatment of colon cancer based on network pharmacology and molecular docking","volume":"14","author":"He","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s10020-024-01033-0","article-title":"Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology","volume":"30","author":"Yao","year":"2024","journal-title":"Mol Med"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0026","doi-asserted-by":"crossref","first-page":"D1465","DOI":"10.1093\/nar\/gkad751","article-title":"TTD: therapeutic Target Database describing target druggability information","volume":"52","author":"Zhou","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0027","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.seizure.2023.09.021","article-title":"Epilepsy-associated genes: an update","volume":"116","author":"Zhang","year":"2024","journal-title":"Seizure"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0028","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0029","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaci.2024.10.015","article-title":"Sensory neuroimmune signaling in the pathogenesis of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"155","author":"Huang","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jdermsci.2024.10.003","article-title":"A carbamazepine metabolite activates NLRP3 and controls skin homing of CD8(+) T-cells in SJS\/TEN","volume":"116","author":"Zhang","year":"2024","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0031","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0032","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0033","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0034","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 Is associated with severity and mortality in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jaad.2010.04.042","article-title":"Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"65","author":"Fujita","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0036","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/exd.14159","article-title":"The role of the renin-angiotensin system in skin physiology and pathophysiology","volume":"29","author":"Silva","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0037","first-page":"732","article-title":"Potential use of angiotensin receptor blockers in skin pathologies","volume":"26","author":"Hedayatyanfard","year":"2023","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0038","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/17512433.2022.2045950","article-title":"Angiotensin converting enzyme and angiotensin converting enzyme inhibitors in dermatology: a narrative review","volume":"15","author":"Lo","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100231","article-title":"Targeting the angiotensin pathway in the treatment of cutaneous fibrosis: a systematic review","volume":"3","author":"Greif","year":"2023","journal-title":"JID Innov"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0040","article-title":"The renin-angiotensin system: the challenge behind autoimmune dermatological diseases","volume":"13","author":"Maranduca","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0041","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.alit.2016.06.003","article-title":"Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions","volume":"66","author":"Komatsu-Fujii","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005113","article-title":"Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-alpha dependent signaling","volume":"10","author":"Aguirre-Ducler","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0043","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1021\/acs.bioconjchem.5c00151","article-title":"Super-sensitive chemiluminescent probe for the detection of caspase-3 activity","volume":"36","author":"Tannous","year":"2025","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0044","article-title":"Distinct roles of PPARs in atherosclerosis","author":"Wang","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/ph18071059","article-title":"Therapeutic effects and mechanisms of the inhaled traditional Chinese medicine compound ZHW on allergic rhinitis","volume":"18","author":"Shen","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0046","article-title":"Treatments for seizures in catamenial (menstrual-related) epilepsy","volume":"9","author":"Maguire","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0047","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1871527319666200819103316","article-title":"Efficacy and tolerability of lacosamide for focal epileptic patients: study from epilepsy clinic in Makkah","volume":"20","author":"Alkhotani","year":"2021","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2024.107339","article-title":"Perampanel for the treatment of epilepsy with genetic aetiology: real-world evidence from the PERMIT Extension study","volume":"202","author":"Delanty","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109369","article-title":"Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: the PERMIT Extension study","volume":"147","author":"Wheless","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0050","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1038\/s41467-024-52990-3","article-title":"Multiomic single-cell sequencing defines tissue-specific responses in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"15","author":"Gibson","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0051","article-title":"Genetics of severe cutaneous adverse reactions","volume":"8","author":"Yang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0052","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/acs.chemrestox.1c00047","article-title":"Extracellular vesicles from human plasma show a distinctive proteome and miRNome profile in patients with severe cutaneous adverse reactions","volume":"34","author":"Salinas-Jaramillo","year":"2021","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0053","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000046362","article-title":"Ocular administration of brinzolamide leading to Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis overlap: a case report and review","volume":"104","author":"Lu","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0054","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0055","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/bcp.70291","article-title":"Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database","volume":"92","author":"Tsuchiya","year":"2026","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0056","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1111\/bcp.15818","article-title":"Integrating real-world data in cost-effectiveness analysis of universal HLA-B*15:02 screening in Malaysia","volume":"89","author":"Chong","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.008_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109787","article-title":"Cost-effectiveness analysis of HLA-B*15:02 screening before treatment of epilepsy in Indonesia","volume":"155","author":"Tanoto","year":"2024","journal-title":"Epilepsy Behav"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:33:30Z","timestamp":1793846010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0149291826002213"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Stevens\u2013Johnson Syndrome\/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}